{"id":"rebif-new-formulation-non-titrated","safety":{"commonSideEffects":[{"rate":"50-70%","effect":"Flu-like symptoms"},{"rate":"30-50%","effect":"Injection site reactions"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"20-40%","effect":"Headache"},{"rate":"10-30%","effect":"Depression"},{"rate":"10-30%","effect":"Anxiety"},{"rate":"5-20%","effect":"Liver enzyme elevations"},{"rate":"5-10%","effect":"Thrombocytopenia"},{"rate":"5-10%","effect":"Leukopenia"}]},"_chembl":{"chemblId":"CHEMBL5283859","moleculeType":null,"molecularWeight":"347.92"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by stimulating the body's immune system to reduce inflammation in the central nervous system, thereby reducing the frequency and severity of MS relapses. Interferon beta-1a has been shown to slow the progression of disability in patients with relapsing forms of MS. However, its exact mechanism of action is not fully understood and may involve multiple pathways.","oneSentence":"Rebif New Formulation Non Titrated is an interferon beta-1a formulation used to treat multiple sclerosis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:25.398Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing forms of multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT00472797","phase":"PHASE3","title":"Rebif New Formulation (RNF) Quality of Life (QOL) Study","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2007-04","conditions":"Relapsing Multiple Sclerosis","enrollment":232}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Rebif New Formulation Non Titrated","genericName":"Rebif New Formulation Non Titrated","companyName":"EMD Serono","companyId":"emd-serono","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rebif New Formulation Non Titrated is an interferon beta-1a formulation used to treat multiple sclerosis. Used for Relapsing forms of multiple sclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}